Intech Investment Management LLC Has $1.93 Million Position in DaVita Inc. $DVA

Key Points

• Intech Investment Management LLC reduced its stake in DaVita Inc. by 53.7%, following the sale of 14,653 shares, bringing its holdings to a total of 12,612 shares valued at approximately $1.93 million.
• Multiple institutional investors have increased their investments in DaVita, with UMB Bank boosting its holdings by 65.5% and National Pension Service raising its position by 74.3%.
• DaVita reported earnings of $2.95 per share, exceeding analyst expectations, and provided a FY 2025 guidance of 10.200-11.300 EPS, indicating a positive outlook for the company.

Intech Investment Management LLC trimmed its stake in DaVita Inc. (NYSE:DVA - Free Report) by 53.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,612 shares of the company's stock after selling 14,653 shares during the quarter. Intech Investment Management LLC's holdings in DaVita were worth $1,929,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of DVA. Invesco Ltd. grew its position in shares of DaVita by 3.4% during the first quarter. Invesco Ltd. now owns 1,642,947 shares of the company's stock worth $251,322,000 after purchasing an additional 53,402 shares in the last quarter. Northern Trust Corp raised its position in DaVita by 20.2% during the 1st quarter. Northern Trust Corp now owns 890,632 shares of the company's stock valued at $136,240,000 after purchasing an additional 149,858 shares in the last quarter. Gates Capital Management Inc. raised its position in shares of DaVita by 0.7% in the 1st quarter. Gates Capital Management Inc. now owns 722,205 shares of the company's stock worth $110,476,000 after acquiring an additional 4,698 shares in the last quarter. Amundi grew its stake in DaVita by 16.0% during the 1st quarter. Amundi now owns 517,690 shares of the company's stock worth $79,584,000 after buying an additional 71,304 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in DaVita by 14.0% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 466,046 shares of the company's stock worth $69,697,000 after buying an additional 57,386 shares during the last quarter. 90.12% of the stock is owned by institutional investors.

DaVita Stock Performance

Shares of DVA stock traded down $0.29 during mid-day trading on Friday, hitting $129.94. 3,137,230 shares of the stock were exchanged, compared to its average volume of 710,700. The stock's fifty day simple moving average is $137.15 and its two-hundred day simple moving average is $141.01. The stock has a market capitalization of $9.29 billion, a price-to-earnings ratio of 12.78, a P/E/G ratio of 0.93 and a beta of 1.13. DaVita Inc. has a 12-month low of $126.07 and a 12-month high of $179.60. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.34 and a current ratio of 1.39.

DaVita (NYSE:DVA - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.70 by $0.25. DaVita had a return on equity of 369.39% and a net margin of 6.35%.The firm had revenue of $3.38 billion for the quarter, compared to analyst estimates of $3.36 billion. During the same quarter last year, the company posted $2.00 earnings per share. The business's revenue was up 6.1% on a year-over-year basis. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. On average, analysts forecast that DaVita Inc. will post 10.76 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on DVA shares. Bank of America decreased their price objective on DaVita from $145.00 to $140.00 and set an "underperform" rating for the company in a report on Wednesday, September 10th. Truist Financial set a $148.00 price target on DaVita in a research report on Friday, August 8th. Wall Street Zen upgraded DaVita from a "hold" rating to a "buy" rating in a research report on Saturday, September 13th. Finally, Barclays dropped their price target on DaVita from $169.00 to $160.00 and set an "equal weight" rating for the company in a research report on Thursday, August 7th. Three investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Reduce" and a consensus price target of $158.00.

Insider Activity

In related news, insider James O. Hearty sold 2,351 shares of DaVita stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $150.00, for a total transaction of $352,650.00. Following the completion of the transaction, the insider directly owned 26,038 shares in the company, valued at $3,905,700. The trade was a 8.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 1.50% of the company's stock.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.